Clinical Trials Logo
  1. Home
  2. NSCLC, Stage I
  3. NCT03446911

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

NSCLC, Stage I Clinical Trial

Official title:
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery: Exploring Safety and Immunological Proof of Principle.

Clinical Trial Summary

This study aims to evaluate the safety and mechanisms of action of the trimodality treatment (radiotherapy, immunotherapy and surgery) in early-stage non-small cell lung cancer. Half of the patients will receive stereotactic ablative radiotherapy followed by 2 cycles of immunotherapy (pembrolizumab); the other half will not receive the immunotherapy treatment. After treatment, both groups will continue treatment according to guidelines and will undergo surgery (lobectomy).

Clinical Trial Description

An open label randomized exploratory study of the safety and mechanisms of action of combined treatment with SBRT and immunotherapy (pembrolizumab, anti-PD1) for early stage NSCLC.

Intervention:

Patients will be randomized between SBRT with or without 2 cycles of pembrolizumab treatment (starting on the first day of radiotherapy). The patients will undergo a lobectomy with hilar and mediastinal lymph node dissection after SBRT +/- pembrolizumab treatment. Translational research to explore the immune mechanism of action will include biological imaging with immuno-PET (positron emission tomography). Expression rates and activation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor draining lymph nodes (TDLNs) by means of fine needle aspirates of TDLNs.

Main study parameters/endpoints:

To assess the safety of combined SBRT and pembrolizumab treatment in early stage NSCLC and to identify the immunological mechanism of action. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03446911
Study type Interventional
Source VU University Medical Center
Contact Eveline A van de Stadt, MD
Phone +31204445242
Email e.vandestadt@vumc.nl
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date March 2018
Completion date May 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05686434 - Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) Phase 2
Recruiting NCT04317534 - Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm Phase 2
Recruiting NCT04205552 - Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients Phase 2
Not yet recruiting NCT06467383 - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting NCT04830826 - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting NCT06404164 - Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection N/A
Recruiting NCT03454685 - The Role of Microbiota on the Development of Lung Cancer
Enrolling by invitation NCT06028412 - Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study N/A
Recruiting NCT03446547 - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) Phase 2